Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions involving the company's Class A common stock. On January 21, Baird sold shares totaling approximately $1.99 million, with sale prices ranging from $28.57 to $29.71 per share.
In addition to the sales, Baird exercised stock options to acquire 67,687 shares at an exercise price of $0.40 per share. This option exercise was part of a pre-established Rule 10b5-1 trading plan adopted on May 30, 2024. Following these transactions, Baird's direct ownership stands at 706,872 shares. The company, now valued at $6.7 billion, maintains a GREAT financial health score according to InvestingPro analysis, with strong liquidity and moderate debt levels.
These transactions were reported in a recent SEC Form 4 filing, reflecting Baird's ongoing involvement in managing her equity stake in the company. For deeper insights into HIMS's valuation, financial health, and 15+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Hims & Hers Health Inc. reported a 77% year-over-year increase in Q3 sales, surpassing $400 million, with an adjusted EBITDA over $50 million. The company also projected Q4 2024 revenue between $465 million and $470 million, marking a significant year-over-year increase. BofA Securities maintained an Underperform rating on Hims & Hers, expressing concerns about the future of the company's compounded GLP-1 products due to defense tactics by pharmaceutical manufacturers. Meanwhile, BTIG initiated coverage with a Buy rating, highlighting the company's innovative business model and robust revenue growth. Needham & Company raised their price target on Hims & Hers and positioned it as their top pick for 2025, citing the company's diverse growth avenues. Morgan Stanley (NYSE:MS) also initiated coverage with an Overweight rating, acknowledging its potential in the digital health and direct-to-consumer sectors. Lastly, the company announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. These are the recent developments for Hims & Hers Health Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.